M ounjaro is the brand name for tirzepatide, a prescription medication developed by Eli Lilly that is primarily used to treat type 2 diabetes in adults. It is a once-weekly inject ...

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 medication injected daily instead of weekly.

Adults receiving tirzepatide lost more weight and had a greater decline in waist circumference than those receiving semaglutide. The proportion of adults experiencing adverse events was similar in ...

MÁLAGA, Spain — In the first head-to-head trial of its kind, tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity; Eli Lilly) produced significantly greater weight loss ...

A major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction than semaglutide, reshaping obesity treatment strategies and offering new hope for patients ...

The SURMOUNT-5 trial, published over the weekend in the New England Journal of Medicine and presented at the European Congress on Obesity, showed that treatment with tirzepatide (Zepbound; Eli Lilly) ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

Compared with semaglutide and insulin, tirzepatide was associated with improved glycemic control and weight loss outcomes among patients with type 2 diabetes. Tirzepatide is associated with longer ...